Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 3/20 | 0.51 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | TCF4 | P15884 | 1/20 | 0.46 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.46 |
| ▸ | NFKBIA | P25963 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.43 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3176961 | 0.92 | LMNA (0.55) | CYP2C9LMNAALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL7284695 | 0.88 | TDP1 (0.51) | CYP2C9LMNAALDH1A1CYP1A2POLB | |
| SCHEMBL9664772 | 0.80 | ALDH1A1 (0.44) | CYP2C9FFAR4LMNAALDH1A1POLB | |
| SCHEMBL9662788 | 0.79 | CYP2C9 (0.48) | CYP2C9FFAR4LMNAALDH1A1POLB | |
| SCHEMBL3263302 | 0.76 | LMNA (0.54) | CYP2C9LMNAALDH1A1CYP1A2POLB | |
| SCHEMBL7166847 | 0.72 | CYP2C9 (0.70) | CYP2C9FFAR4LMNAALDH1A1CYP1A2 | |
| SCHEMBL3177473 | 0.72 | LMNA (0.58) | CYP2C9LMNAALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL9664312 | 0.72 | NOD1 (0.51) | LMNAALDH1A1POLBCYP3A4MAPT | |
| SCHEMBL9430191 | 0.70 | AGTR1 (0.43) | CYP2C9ALDH1A1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL9430194 | 0.70 | CYP3A4 (0.44) | CYP2C9LMNAALDH1A1CYP1A2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100010035-A1 | Novel Dual Action Receptors Antagonists (Dara) at the Ati and Eta Receptors | TORRENT PHARMACEUTICALS LTD. (IN) | 2010-01-14 | — | — | US | disclosed |
| US-20100010035-A1 | Novel Dual Action Receptors Antagonists (Dara) at the Ati and Eta Receptors | TORRENT PHARMACEUTICALS LTD. (IN) | 2010-01-14 | — | — | US | disclosed |
| US-20100010035-A1 | Novel Dual Action Receptors Antagonists (Dara) at the Ati and Eta Receptors | TORRENT PHARMACEUTICALS LTD. (IN) | 2010-01-14 | — | — | US | disclosed |
| EP-1996588-A1 | NOVEL DUAL ACTION RECEPTORS ANTAGONISTS (DARA) AT THE ATI AND ETA RECEPTORS | Torrent Pharmaceuticals Ltd (IN) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007100295-A1 | NOVEL DUAL ACTION RECEPTORS ANTAGONISTS (DARA) AT THE ATI AND ETA RECEPTORS | TORRENT PHARMACEUTICALS LTD (IN) | 2007-09-07 | — | — | WO | disclosed |
| WO-2007100295-A1 | NOVEL DUAL ACTION RECEPTORS ANTAGONISTS (DARA) AT THE ATI AND ETA RECEPTORS | TORRENT PHARMACEUTICALS LTD (IN) | 2007-09-07 | — | — | WO | disclosed |
| EP-0516392-B1 | Naphthyridine derivatives as angiotensin II inhibitors | ASTRAZENECA AB (SE) | 2001-08-29 | — | — | EP | disclosed |
| US-5294620-A | Hypotensive agents or compounds for cardiovascular disorders | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-03-15 | — | — | US | disclosed |
| WO-1993024501-A1 | PHOSPHORUS CONTAINING HETEROCYCLIC COMPOUNDS AS ANGIOTENSINS ANTAGONISTS | ZENECA LIMITED (GB) | 1993-12-09 | — | — | WO | disclosed |
| WO-1993024487-A1 | NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS AS ANGIOTENSIN-II-ANTAGONISTS | ZENECA LIMITED (GB) | 1993-12-09 | — | — | WO | disclosed |
| US-5217976-A | Hypotensive agents, congestive heart failure | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-06-08 | — | — | US | disclosed |
| EP-0516392-A2 | Naphthyridine derivatives as angiotensin II inhibitors | ZENECA LIMITED (GB) | 1992-12-02 | — | — | EP | disclosed |
| EP-0511791-A2 | Pyrrolopyridine derivatives as Angiotensin inhibitors | ZENECA LIMITED (GB) | 1992-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010035-A1 | Novel Dual Action Receptors Antagonists (Dara) at the Ati and Eta Receptors | EDNRA, EDNRB, AGTR1 | CYP2C9 2139/4885FFAR4 385/4885LMNA 2967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.